para pacientes y familiares
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer | Journal of Clinical Oncology
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing...
The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m2 once a week for seven c...
ascopubs.org
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study | Journal of Clinical Oncology
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor...
Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective respons...
ascopubs.org
Visión de los expertos sobre los nuevos retos en cáncer de nasofaringe. Webinar martes 16 de junio a las 16 h. Programa y registro en https://www.ttccgrupo.com
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer | Journal of Clinical Oncology
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing...
The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m2 once a week for seven c...
ascopubs.org
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study | Journal of Clinical Oncology
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor...
Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective respons...
ascopubs.org
Visión de los expertos sobre los nuevos retos en cáncer de nasofaringe. Webinar martes 16 de junio a las 16 h. Programa y registro en https://www.ttccgrupo.com
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer | Journal of Clinical Oncology
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing...
The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m2 once a week for seven c...
ascopubs.org
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study | Journal of Clinical Oncology
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor...
Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective respons...
ascopubs.org
Visión de los expertos sobre los nuevos retos en cáncer de nasofaringe. Webinar martes 16 de junio a las 16 h. Programa y registro en https://www.ttccgrupo.com
TTCC en cifras
